DENVER, Feb. 22 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation announced today that the editorial reviewers for two annual scientific meetings have accepted Accelr8 scientists’ submissions for technical poster presentations. These events represent the company’s first disclosures to the scientific community of the technical principles used in its BACcelr8r(TM) rapid pathogen diagnostic development program. The posters will present data on fundamental scientific elements of the company’s methods for bacterial analysis (identification, counting, growth measurement, and antibiotic resistance testing).
According to David Howson, Accelr8’s president, “these presentations will mark Accelr8’s first exposure to the scientific community of our unique Quantum Microbiology(TM) methods for rapid pathogen analysis. They reflect our progress in eliminating bacterial cultures along our path toward rapid, improved measurement of antibiotic resistance in life-threatening hospital acquired infections.”
The 38th annual Oak Ridge Conference, entitled “Pushing the Technology Envelope III: The Next Generations of Diagnostic Testing” will be held on April 20-21 in San Jose, Calif. It is sponsored by the American Association for Clinical Chemistry (AACC, www.aacc.org). The AACC is a large, US-based international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals engaged in science-related clinical laboratory disciplines. The Oak Ridge Conference is the AACC venue for new science and technology in emerging diagnostics.
At this conference, Accelr8 scientists will present two technical posters. The first will present data derived from novel methods for rapid bacterial concentration and rapid species identification in a fluidic device. The second will report growth rate measurements of individual bacteria and their descendant clones in the same type of fluidic device.
The second meeting will be the 106th General Meeting of the American Society for Microbiology (ASM, www.asm.org), being held May 21-25 in Orlando, Fla. The ASM is the leading American professional society for microbiologists. At this annual meeting, Accelr8 scientists will present data derived from a rapid, clinically-relevant test for an important type of antibiotic resistance that has proven difficult to accurately test with automated commercial instruments.
“We look forward to engaging the microbiology community in applying our technology for rapid bacterial analysis without culturing,” said Howson. “These presentations are the first in what we plan to become a growing pipeline of peer-reviewed publications that are subjected to independent scientific scrutiny. In this early phase we will report the results of basic studies using our innovative scientific principles. We then intend to progress to demonstrations of increasingly practical clinical application. We intend ultimately to validate the BACcelr8r as an important new diagnostic advance in managing critically ill patients who contract a drug-resistant hospital acquired infection (HAI).”
ABOUT ACCELR8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical diagnostics, basic research, drug discovery, and bio-detection. Accelr8 is developing a new diagnostic platform, the BACcelr8r(TM), based on its proprietary surface coatings, assay processing, and detection technologies. The company intends the BACcelr8r(TM) to become the world’s first diagnostic system to provide bacterial identification and quantitation in 2 hours or less, and complete antibiotic resistance strain identification in 8 hours or less. Standard culturing typically delays lab results from one to three days, which is far beyond the short time window that physicians have available to assure adequate initial therapy for a life-threatening hospital acquired infection (HAI).
Safe Harbor for Forward-Looking Statements
Certain statements in this news release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company’s filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.
Accelr8 Technology Corporation
CONTACT: John Metzger of Metzger Associates, +1-303-786-7000, ext. 2202,john@metzger.com, for Accelr8 Technology Corporation; or David Howson ofAccelr8 Technology Corporation, +1-303-863-8088, david.howson@accelr8.com
